STOCK TITAN

BiomX (PHGE) Stock News, Aug-Nov 2024

PHGE NYSE

Ticker history: PHGE became HLSQ (Tessera Defense and Homeland Security Inc.) on .

Historical ticker: BiomX Inc. changed its name to Tessera Defense and Homeland Security Inc. and began trading as HLSQ on September 11, 2026. PHGE news and SEC filings are retained here with their original names and dates. The profile below describes the earlier BiomX business.

BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.

PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.

Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.

BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.

Rhea-AI Summary

BiomX announced Q3 2024 financial results and clinical program updates. Patient enrollment for BX211 Phase 2 trial in Diabetic Foot Osteomyelitis is complete, with topline results expected in Q1 2025. The BX004 Phase 2b study in Cystic Fibrosis faced manufacturing delays, now resolved, with results expected in H1 2026. Cash balance was $24.7M as of September 30, 2024. R&D expenses increased to $7.3M from $5.6M year-over-year. The company reported net income of $9.6M compared to a net loss of $7.9M in Q3 2023, mainly due to changes in warrant fair value. Cash runway extends into Q4 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on natural and engineered phage therapies, has scheduled a conference call and webcast for November 14, 2024, at 8:00 a.m. ET. The event will cover the company's third quarter 2024 financial results, business updates, and program developments. Participants can join via phone at 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
conferences earnings date
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing phage therapies targeting specific pathogenic bacteria, has announced a mandatory separation of its units (PHGE.U). Each unit consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock. The separation will occur on or about October 25, 2024, after which the units will no longer trade on the NYSE American.

Key points:

  • Unit holders will receive the underlying shares of Common Stock and Warrants
  • The separation is automatic, requiring no action from unit holders
  • Warrants will expire on October 28, 2024
  • Each warrant allows purchase of one-half share at $115 per share
  • Post-separation, Common Stock will trade under the symbol PHGE
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) will present updated data from its Phase 1b/2a study of BX004 for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at the North American Cystic Fibrosis Conference in Boston. The findings will be showcased in a poster session on September 27, 2024, and discussed in a workshop on September 28, 2024.

Key results include:

  • Greater reduction in P. aeruginosa colony-forming units in subjects receiving BX004-A compared to placebo
  • 14% of BX004-A recipients had negative P. aeruginosa sputum culture at treatment end, versus 0% for placebo
  • Improved lung function (FEV1) in a subgroup of BX004-A recipients (+5.66%) compared to placebo (-3.23%)

The study's six-month follow-up has been completed for all subjects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel phage therapies targeting specific pathogenic bacteria, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel.

Key details include:

  • CEO Jonathan Solomon will present a corporate overview
  • Presentation Date: September 9, 2024
  • Time: Available on-demand from 7:00 AM ET
  • Webcast link provided for virtual attendance
  • Replay available on BiomX's website for 90 days

Mr. Solomon will also be available for one-on-one meetings during the conference. Interested parties can register and request meetings through the provided link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) will present positive Phase 1b/2a clinical trial data for BX004, a novel phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients, at the European Respiratory Society Congress 2024. The study demonstrated favorable safety and notable microbiologic and clinical efficacy, even in patients on standard care treatment. Key findings include:

1. Greater reduction in P. aeruginosa colony-forming units in treated subjects vs. placebo
2. 14% of treated subjects had negative P. aeruginosa sputum culture at treatment end
3. Improved lung function in a subgroup of treated patients
4. No treatment-related phage resistance or serious adverse events

BiomX CEO Jonathan Solomon expressed encouragement about the results, highlighting the potential of their novel approach in treating cystic fibrosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.38%
Tags
conferences clinical trial
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) has announced a 1-for-10 reverse stock split of its common stock, effective August 26, 2024. The stock will continue trading under the symbol 'PHGE' with a new CUSIP number. This decision follows stockholder approval on July 9, 2024, and final ratio determination by the Board on August 8, 2024. The split will reduce outstanding shares from approximately 178,958,447 to 17,895,845.

Key points:

  • Proportional adjustments will be made to equity awards, warrants, convertible preferred stock, and stock incentive plans
  • Outstanding units will also undergo a 1-for-10 reverse split, trading under 'PHGE U'
  • No fractional shares will be issued; stockholders entitled to fractional shares will receive an additional fraction to round up
  • The split won't alter stockholders' percentage ownership, except for minor fractional share adjustments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) has announced a 1-for-10 reverse stock split of its common stock, effective August 26, 2024. The stock will continue trading under the symbol 'PHGE' with a new CUSIP number. This decision, approved by stockholders on July 9, 2024, will reduce outstanding shares from approximately 178,958,447 to 17,895,845. The reverse split will not alter stockholders' ownership percentages, and fractional shares will be rounded up. No action is required for holders of book-entry or brokerage account shares. The company's units will be proportionally adjusted, maintaining one share and one warrant exercisable for half a share per unit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.58%
Tags
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) reported Q2 2024 financial results and provided business updates. Key highlights include:

1. Anticipated readout of topline results for BX211 in Q1 2025 for diabetic foot osteomyelitis treatment.

2. Planned initiation of BX004 Phase 2b trial for cystic fibrosis, with results expected in Q3 2025.

3. Stockholder approval for conversion of Series X Preferred Stock to common stock.

4. Cash balance of $32.7 million as of June 30, 2024, sufficient to fund operations through Q4 2025.

5. Net income of $4.5 million for Q2 2024, compared to a net loss of $6.4 million in Q2 2023.

6. R&D expenses increased to $6.9 million in Q2 2024 from $3.8 million in Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.58%
Tags
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel natural and engineered phage therapies targeting specific pathogenic bacteria, has announced a conference call and live audio webcast scheduled for August 15, 2024, at 8:00 a.m. ET. The purpose of this event is to report the company's second quarter 2024 financial results and provide updates on its business and programs.

Interested parties can participate in the conference call by dialing 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). Additionally, a live and archived webcast will be available in the Investors section of the BiomX website at www.biomx.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences earnings date

FAQ

What is the current stock price of BiomX (PHGE)?

BiomX (PHGE) last closed at $1.85. The company now trades as HLSQ.